KNSA
Kiniksa Pharmaceuticals International PLC
$
33.650
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
33.660
Open
32.960
VWAP
33.37
Vol
573.20K
Mkt Cap
2.49B
Low
32.685
Amount
19.13M
EV/EBITDA(TTM)
354.94
Total Shares
70.94M
EV
2.12B
EV/OCF(TTM)
31.69
P/S(TTM)
4.62
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
166.73M
+48.58%
0.365
-302.78%
176.31M
+43.88%
0.425
-454.51%
189.30M
+37.39%
0.240
+118.18%
Estimates Revision
The market is revising Upward the revenue expectations for Kiniksa Pharmaceuticals International, plc (KNSA) for FY2025, with the revenue forecasts being adjusted by 6.49% over the past three months. During the same period, the stock price has changed by 34.44%.
Revenue Estimates for FY2025
Revise Upward
+6.49%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+39.39%
In Past 3 Month
Stock Price
Go Up
+34.44%
In Past 3 Month
6 Analyst Rating
20.86% Upside
Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 40.67 USD with a low forecast of 33.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
20.86% Upside
Current: 33.650
Low
33.00
Averages
40.67
High
54.00
20.86% Upside
Current: 33.650
Low
33.00
Averages
40.67
High
54.00
Jefferies
Buy
maintain
$45 -> $54
2025-07-29
Reason
Jefferies
Price Target
$45 -> $54
2025-07-29
maintain
Buy
Reason
Jefferies raised the firm's price target on Kiniksa to $54 from $45 and keeps a Buy rating on the shares after what the firm points out was "another 'beat & raise'" report following a "greatly positive" Q1. The firm sees strong commercial execution, continued growth on all launch metrics, and meaningful upside from further deepening the penetration into the target population as well as potential expansion into a larger population of patients, the analyst tells investors.
Wells Fargo
NULL -> Overweight
upgrade
$30 -> $42
2025-07-09
Reason
Wells Fargo
Price Target
$30 -> $42
2025-07-09
upgrade
NULL -> Overweight
Reason
Wells Fargo raised the firm's price target on Kiniksa to $42 from $30 and keeps an Overweight rating on the shares. The firm's Q2 Arcalyst estimates of $146M are in line with the Street, and it forecasts continued growth through 2025. As KPL-387's trial initiates in mid-25, all eyes are on Arcalyst this year and its market share in early lines, adds Wells.
Wedbush
David Nierengarten
Buy
Reiterates
$34
2025-04-16
Reason
Wedbush
David Nierengarten
Price Target
$34
2025-04-16
Reiterates
Buy
Reason
Citigroup
Geoff Meacham
Strong Buy
Initiates
$40
2025-03-13
Reason
Citigroup
Geoff Meacham
Price Target
$40
2025-03-13
Initiates
Strong Buy
Reason
Citi initiated coverage of Kiniksa with a Buy rating and $40 price target. Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term "choppiness," a "barbell approach" to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi's preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are "clean growth stories." The firm highlights Apogee, Avidity, and Kymera as favorites.
JP Morgan
Anupam Rama
Buy
Maintains
$39 → $40
2024-11-05
Reason
JP Morgan
Anupam Rama
Price Target
$39 → $40
2024-11-05
Maintains
Buy
Reason
Evercore ISI Group
Liisa Bayko
Buy
Maintains
$30 → $35
2024-10-30
Reason
Evercore ISI Group
Liisa Bayko
Price Target
$30 → $35
2024-10-30
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Kiniksa Pharmaceuticals International PLC (KNSA.O) is 23.24, compared to its 5-year average forward P/E of -291.69. For a more detailed relative valuation and DCF analysis to assess Kiniksa Pharmaceuticals International PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-291.69
Current PE
23.24
Overvalued PE
975.50
Undervalued PE
-1558.89
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-28.24
Current EV/EBITDA
16.73
Overvalued EV/EBITDA
121.44
Undervalued EV/EBITDA
-177.92
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
21.45
Current PS
3.34
Overvalued PS
82.39
Undervalued PS
-39.48
Financials
Annual
Quarterly
FY2025Q2
YoY :
+44.34%
156.80M
Total Revenue
FY2025Q2
YoY :
-17330.77%
20.16M
Operating Profit
FY2025Q2
YoY :
-556.29%
17.83M
Net Income after Tax
FY2025Q2
YoY :
-483.33%
0.23
EPS - Diluted
FY2025Q2
YoY :
+440.34%
27.93M
Free Cash Flow
FY2025Q2
YoY :
-0.59%
88.14
Gross Profit Margin - %
FY2025Q2
YoY :
+40.49%
12.56
FCF Margin - %
FY2025Q2
YoY :
-415.83%
11.37
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 1139.5% over the last month.
Sold
0-3
Months
12.5M
USD
15
3-6
Months
11.1M
USD
26
6-9
Months
1.9M
USD
8
0-12
Months
6.9M
USD
8
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.5M
Volume
1
6-9
Months
1.0M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
1.4M
Volume
Months
6-9
3
758.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 1139.5% over the last month.
Sold
0-3
Months
12.5M
USD
15
3-6
Months
11.1M
USD
26
6-9
Months
1.9M
USD
8
0-12
Months
6.9M
USD
8
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KNSA News & Events
Events Timeline
2025-07-29 (ET)
2025-07-29
07:36:42
Kiniksa raises FY25 ARCALYST revenue view to $625M-$640M from $590M-$605M
2025-07-29
07:35:40
Kiniksa reports Q2 EPS 23c, consensus 26c
2025-06-05 (ET)
2025-06-05
07:03:40
Kiniksa announces details for planned 2/3 trial of KPL-387
Sign Up For More Events
Sign Up For More Events
News
9.5
08-13NASDAQ.COMTheravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
8.5
08-04BenzingaWhy CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
4.0
07-29BenzingaJefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $54
Sign Up For More News
People Also Watch
BHLB
Berkshire Hills Bancorp Inc
26.120
USD
+2.51%
SILA
Sila Realty Trust Inc
24.820
USD
-2.13%
BLBD
Blue Bird Corp
56.480
USD
-0.02%
AMC
AMC Entertainment Holdings Inc
3.070
USD
0.00%
SGML
Sigma Lithium Corp
5.860
USD
-5.79%
TPC
Tutor Perini Corp
57.750
USD
-1.74%
SCS
Steelcase Inc
16.360
USD
+1.05%
RBCAA
Republic Bancorp Inc
73.090
USD
+2.42%
USPH
US Physical Therapy Inc
88.520
USD
+1.18%
GEL
Genesis Energy LP
16.990
USD
+2.04%
FAQ
What is Kiniksa Pharmaceuticals International PLC (KNSA) stock price today?
The current price of KNSA is 33.65 USD — it has increased 2.65 % in the last trading day.
What is Kiniksa Pharmaceuticals International PLC (KNSA)'s business?
What is the price predicton of KNSA Stock?
What is Kiniksa Pharmaceuticals International PLC (KNSA)'s revenue for the last quarter?
What is Kiniksa Pharmaceuticals International PLC (KNSA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Kiniksa Pharmaceuticals International PLC (KNSA)'s fundamentals?
How many employees does Kiniksa Pharmaceuticals International PLC (KNSA). have?